Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transcatheter Aortic Valve Replacement | 14 | 2022 | 90 | 5.280 |
Why?
|
Aortic Valve Stenosis | 16 | 2022 | 177 | 4.360 |
Why?
|
Angioplasty, Balloon, Coronary | 35 | 2012 | 178 | 3.940 |
Why?
|
Coronary Artery Disease | 28 | 2020 | 696 | 3.030 |
Why?
|
Heart Valve Prosthesis Implantation | 9 | 2022 | 164 | 2.670 |
Why?
|
Coronary Angiography | 47 | 2021 | 866 | 2.600 |
Why?
|
Drug-Eluting Stents | 20 | 2012 | 51 | 2.600 |
Why?
|
Cardiac Catheterization | 17 | 2022 | 419 | 2.340 |
Why?
|
Stents | 22 | 2022 | 657 | 1.910 |
Why?
|
Aortic Valve | 14 | 2022 | 249 | 1.900 |
Why?
|
Coronary Restenosis | 18 | 2016 | 42 | 1.730 |
Why?
|
Heart Valve Prosthesis | 6 | 2020 | 222 | 1.570 |
Why?
|
Computed Tomography Angiography | 11 | 2021 | 424 | 1.500 |
Why?
|
Fractional Flow Reserve, Myocardial | 11 | 2021 | 137 | 1.440 |
Why?
|
Coronary Stenosis | 13 | 2018 | 246 | 1.330 |
Why?
|
Ultrasonography, Interventional | 12 | 2019 | 119 | 1.280 |
Why?
|
Myocardial Infarction | 21 | 2013 | 807 | 1.240 |
Why?
|
Tomography, X-Ray Computed | 15 | 2022 | 2324 | 1.120 |
Why?
|
Sirolimus | 13 | 2012 | 118 | 1.110 |
Why?
|
Calcinosis | 5 | 2019 | 241 | 1.100 |
Why?
|
Coronary Thrombosis | 10 | 2009 | 45 | 1.060 |
Why?
|
Cardiovascular Agents | 6 | 2012 | 82 | 1.030 |
Why?
|
Foramen Ovale, Patent | 4 | 2015 | 21 | 1.010 |
Why?
|
Coronary Vessels | 11 | 2022 | 313 | 1.000 |
Why?
|
Paclitaxel | 11 | 2012 | 140 | 0.940 |
Why?
|
Percutaneous Coronary Intervention | 5 | 2019 | 137 | 0.850 |
Why?
|
Mitral Valve Insufficiency | 4 | 2018 | 99 | 0.840 |
Why?
|
Humans | 116 | 2022 | 68549 | 0.840 |
Why?
|
Coronary Occlusion | 2 | 2020 | 12 | 0.810 |
Why?
|
Plaque, Atherosclerotic | 5 | 2016 | 125 | 0.810 |
Why?
|
Bioprosthesis | 3 | 2018 | 101 | 0.800 |
Why?
|
Treatment Outcome | 47 | 2022 | 7028 | 0.770 |
Why?
|
Prosthesis Design | 17 | 2018 | 301 | 0.710 |
Why?
|
Heart Valve Diseases | 3 | 2022 | 123 | 0.710 |
Why?
|
Mitral Valve | 4 | 2018 | 166 | 0.710 |
Why?
|
Retrospective Studies | 48 | 2021 | 7268 | 0.690 |
Why?
|
Heparin | 8 | 2017 | 205 | 0.680 |
Why?
|
Hemodynamic Monitoring | 1 | 2019 | 6 | 0.670 |
Why?
|
Coronary Disease | 7 | 2008 | 358 | 0.640 |
Why?
|
Coronary Artery Bypass | 7 | 2022 | 218 | 0.640 |
Why?
|
Male | 86 | 2022 | 37283 | 0.640 |
Why?
|
Aged | 63 | 2022 | 14842 | 0.640 |
Why?
|
Contrast Media | 7 | 2016 | 595 | 0.630 |
Why?
|
Middle Aged | 67 | 2022 | 21119 | 0.610 |
Why?
|
Anticoagulants | 6 | 2017 | 356 | 0.610 |
Why?
|
Iliac Artery | 2 | 2015 | 44 | 0.600 |
Why?
|
Female | 82 | 2022 | 38021 | 0.600 |
Why?
|
Septal Occluder Device | 2 | 2015 | 21 | 0.590 |
Why?
|
Thoracotomy | 1 | 2017 | 25 | 0.580 |
Why?
|
Autonomic Nerve Block | 1 | 2017 | 15 | 0.580 |
Why?
|
Secondary Prevention | 3 | 2015 | 291 | 0.570 |
Why?
|
Peptide Fragments | 6 | 2012 | 483 | 0.570 |
Why?
|
Hemodynamics | 9 | 2022 | 705 | 0.570 |
Why?
|
Radial Artery | 2 | 2019 | 43 | 0.560 |
Why?
|
Hirudins | 6 | 2012 | 32 | 0.560 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 167 | 0.560 |
Why?
|
Saphenous Vein | 4 | 2009 | 61 | 0.540 |
Why?
|
Graft Occlusion, Vascular | 4 | 2009 | 73 | 0.540 |
Why?
|
Acute Coronary Syndrome | 4 | 2017 | 195 | 0.510 |
Why?
|
Angina Pectoris | 4 | 2013 | 61 | 0.510 |
Why?
|
Aortography | 1 | 2015 | 72 | 0.510 |
Why?
|
Hemorrhage | 5 | 2017 | 328 | 0.500 |
Why?
|
Pain, Postoperative | 1 | 2017 | 214 | 0.490 |
Why?
|
Time Factors | 24 | 2018 | 4655 | 0.470 |
Why?
|
Arteries | 2 | 2020 | 108 | 0.470 |
Why?
|
Cardiovascular Diseases | 7 | 2010 | 938 | 0.460 |
Why?
|
Machine Learning | 4 | 2019 | 170 | 0.460 |
Why?
|
Platelet Aggregation Inhibitors | 8 | 2012 | 373 | 0.450 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2012 | 80 | 0.430 |
Why?
|
Feasibility Studies | 9 | 2022 | 652 | 0.430 |
Why?
|
Predictive Value of Tests | 16 | 2020 | 1465 | 0.420 |
Why?
|
Fluoroscopy | 3 | 2020 | 152 | 0.420 |
Why?
|
Thrombosis | 6 | 2010 | 218 | 0.410 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 201 | 0.410 |
Why?
|
Risk Assessment | 15 | 2021 | 2004 | 0.410 |
Why?
|
Vascular Calcification | 3 | 2019 | 131 | 0.400 |
Why?
|
Prosthesis Failure | 2 | 2015 | 130 | 0.400 |
Why?
|
Severity of Illness Index | 17 | 2019 | 1851 | 0.400 |
Why?
|
Shock, Cardiogenic | 3 | 2018 | 23 | 0.400 |
Why?
|
Heart | 2 | 2016 | 850 | 0.390 |
Why?
|
Pulmonary Wedge Pressure | 3 | 2022 | 102 | 0.380 |
Why?
|
Angina, Unstable | 2 | 2008 | 50 | 0.370 |
Why?
|
Patient Safety | 1 | 2012 | 202 | 0.350 |
Why?
|
Aged, 80 and over | 16 | 2022 | 4843 | 0.350 |
Why?
|
Metals | 6 | 2010 | 100 | 0.350 |
Why?
|
Ticlopidine | 5 | 2009 | 118 | 0.330 |
Why?
|
Risk Factors | 18 | 2019 | 5720 | 0.320 |
Why?
|
Prospective Studies | 12 | 2022 | 3703 | 0.310 |
Why?
|
Spectroscopy, Near-Infrared | 4 | 2013 | 31 | 0.310 |
Why?
|
Follow-Up Studies | 21 | 2021 | 3256 | 0.300 |
Why?
|
Balloon Occlusion | 1 | 2007 | 22 | 0.300 |
Why?
|
Prognosis | 9 | 2019 | 2093 | 0.290 |
Why?
|
Hypertension, Pulmonary | 2 | 2020 | 232 | 0.290 |
Why?
|
Device Removal | 1 | 2007 | 100 | 0.280 |
Why?
|
Blood Pressure | 3 | 2022 | 1449 | 0.270 |
Why?
|
Stroke | 4 | 2015 | 2162 | 0.270 |
Why?
|
Registries | 8 | 2019 | 730 | 0.270 |
Why?
|
Preoperative Care | 3 | 2021 | 275 | 0.270 |
Why?
|
Thermography | 1 | 2005 | 20 | 0.270 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 236 | 0.250 |
Why?
|
Reproducibility of Results | 10 | 2020 | 2077 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 9 | 2012 | 536 | 0.230 |
Why?
|
Recombinant Proteins | 6 | 2012 | 742 | 0.230 |
Why?
|
Heart Failure | 4 | 2022 | 1179 | 0.220 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 4 | 2019 | 373 | 0.220 |
Why?
|
ROC Curve | 7 | 2017 | 392 | 0.220 |
Why?
|
Germany | 4 | 2016 | 67 | 0.210 |
Why?
|
Vena Cava, Superior | 1 | 2022 | 41 | 0.200 |
Why?
|
Decision Making | 2 | 2017 | 410 | 0.200 |
Why?
|
Aneurysm, False | 1 | 2022 | 60 | 0.200 |
Why?
|
Recurrence | 6 | 2015 | 948 | 0.200 |
Why?
|
Patient Selection | 4 | 2013 | 592 | 0.190 |
Why?
|
Catheterization, Peripheral | 2 | 2019 | 38 | 0.190 |
Why?
|
Heart Atria | 1 | 2022 | 206 | 0.190 |
Why?
|
Lipids | 2 | 2013 | 298 | 0.190 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2020 | 25 | 0.180 |
Why?
|
Multimodal Imaging | 2 | 2022 | 62 | 0.180 |
Why?
|
Tubulin Modulators | 2 | 2012 | 10 | 0.180 |
Why?
|
Immunosuppressive Agents | 5 | 2012 | 514 | 0.180 |
Why?
|
Transposition of Great Vessels | 1 | 2020 | 51 | 0.180 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2013 | 116 | 0.180 |
Why?
|
Echocardiography, Transesophageal | 3 | 2015 | 100 | 0.170 |
Why?
|
Japan | 1 | 2019 | 68 | 0.170 |
Why?
|
Catheters | 1 | 2019 | 39 | 0.170 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.170 |
Why?
|
Obesity | 2 | 2017 | 1074 | 0.170 |
Why?
|
Myocardial Ischemia | 3 | 2013 | 172 | 0.170 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 75 | 0.160 |
Why?
|
Radiation Dosage | 3 | 2016 | 419 | 0.160 |
Why?
|
Triiodobenzoic Acids | 2 | 2015 | 28 | 0.160 |
Why?
|
Cardiac-Gated Imaging Techniques | 2 | 2015 | 60 | 0.160 |
Why?
|
Patient Care Planning | 2 | 2015 | 108 | 0.160 |
Why?
|
Pulmonary Artery | 1 | 2020 | 323 | 0.160 |
Why?
|
Sensitivity and Specificity | 6 | 2019 | 1753 | 0.160 |
Why?
|
Blood Vessel Prosthesis Implantation | 3 | 2008 | 186 | 0.150 |
Why?
|
Equipment Design | 3 | 2012 | 500 | 0.150 |
Why?
|
Myocardial Revascularization | 2 | 2008 | 56 | 0.150 |
Why?
|
Coated Materials, Biocompatible | 2 | 2008 | 54 | 0.150 |
Why?
|
Echocardiography | 2 | 2022 | 515 | 0.150 |
Why?
|
Heart Diseases | 3 | 2009 | 276 | 0.150 |
Why?
|
Ventricular Function, Right | 1 | 2018 | 103 | 0.150 |
Why?
|
Prosthesis Implantation | 1 | 2018 | 83 | 0.150 |
Why?
|
Coronary Circulation | 3 | 2013 | 136 | 0.140 |
Why?
|
Adult | 12 | 2022 | 21379 | 0.140 |
Why?
|
Incidence | 6 | 2013 | 1582 | 0.140 |
Why?
|
Survival Rate | 5 | 2017 | 1055 | 0.140 |
Why?
|
South Carolina | 2 | 2013 | 2752 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 3 | 2016 | 2222 | 0.130 |
Why?
|
Thrombectomy | 2 | 2009 | 238 | 0.130 |
Why?
|
Everolimus | 2 | 2012 | 26 | 0.130 |
Why?
|
Signal-To-Noise Ratio | 1 | 2015 | 93 | 0.130 |
Why?
|
Heart-Assist Devices | 1 | 2018 | 221 | 0.130 |
Why?
|
Cohort Studies | 5 | 2017 | 2356 | 0.120 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 481 | 0.120 |
Why?
|
Ethanol | 2 | 2013 | 892 | 0.120 |
Why?
|
Multidetector Computed Tomography | 1 | 2014 | 60 | 0.120 |
Why?
|
Forecasting | 1 | 2015 | 277 | 0.110 |
Why?
|
Patient Outcome Assessment | 1 | 2013 | 42 | 0.110 |
Why?
|
Embolism, Paradoxical | 1 | 2013 | 6 | 0.110 |
Why?
|
Disease Progression | 3 | 2019 | 1037 | 0.110 |
Why?
|
Logistic Models | 6 | 2016 | 1419 | 0.110 |
Why?
|
Troponin I | 2 | 2011 | 34 | 0.110 |
Why?
|
Blood Flow Velocity | 1 | 2013 | 172 | 0.110 |
Why?
|
Ablation Techniques | 1 | 2013 | 33 | 0.110 |
Why?
|
Deep Sedation | 1 | 2012 | 11 | 0.110 |
Why?
|
Anesthesia, Local | 1 | 2012 | 14 | 0.110 |
Why?
|
Sympathectomy | 1 | 2012 | 24 | 0.110 |
Why?
|
Angiography | 1 | 2013 | 194 | 0.110 |
Why?
|
Mitral Valve Annuloplasty | 1 | 2012 | 6 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2011 | 1615 | 0.100 |
Why?
|
Embolism, Cholesterol | 1 | 2011 | 3 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2016 | 1046 | 0.100 |
Why?
|
Electrocardiography | 3 | 2009 | 601 | 0.100 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 65 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 689 | 0.100 |
Why?
|
Acute Disease | 3 | 2009 | 658 | 0.100 |
Why?
|
Drug Utilization | 1 | 2012 | 119 | 0.100 |
Why?
|
Creatine Kinase, MB Form | 2 | 2008 | 20 | 0.100 |
Why?
|
Area Under Curve | 3 | 2016 | 238 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2012 | 127 | 0.090 |
Why?
|
Vascular Patency | 3 | 2019 | 122 | 0.090 |
Why?
|
Angioplasty | 1 | 2011 | 118 | 0.090 |
Why?
|
Cardiology | 1 | 2012 | 140 | 0.090 |
Why?
|
Reoperation | 2 | 2009 | 467 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2012 | 229 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2008 | 249 | 0.090 |
Why?
|
Tomography, Spiral Computed | 1 | 2009 | 57 | 0.090 |
Why?
|
Peripheral Vascular Diseases | 1 | 2009 | 50 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2009 | 791 | 0.090 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2009 | 14 | 0.090 |
Why?
|
Biomarkers | 5 | 2019 | 1593 | 0.090 |
Why?
|
Suction | 1 | 2009 | 33 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2010 | 122 | 0.080 |
Why?
|
Elasticity Imaging Techniques | 1 | 2009 | 14 | 0.080 |
Why?
|
Femoral Artery | 1 | 2009 | 139 | 0.080 |
Why?
|
Safety | 2 | 2007 | 145 | 0.080 |
Why?
|
Embolism | 1 | 2008 | 45 | 0.080 |
Why?
|
Emergencies | 1 | 2009 | 107 | 0.080 |
Why?
|
Filtration | 1 | 2008 | 61 | 0.080 |
Why?
|
Platelet Membrane Glycoprotein IIb | 1 | 2008 | 4 | 0.080 |
Why?
|
Tomography, Optical Coherence | 1 | 2009 | 88 | 0.080 |
Why?
|
Iopamidol | 1 | 2008 | 37 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 137 | 0.080 |
Why?
|
Length of Stay | 1 | 2012 | 780 | 0.080 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2009 | 85 | 0.080 |
Why?
|
Heart Septum | 1 | 2008 | 84 | 0.080 |
Why?
|
Integrin beta3 | 1 | 2008 | 35 | 0.080 |
Why?
|
Hospital Mortality | 4 | 2013 | 384 | 0.080 |
Why?
|
Stroke Volume | 2 | 2022 | 586 | 0.080 |
Why?
|
Device Approval | 1 | 2007 | 6 | 0.080 |
Why?
|
Body Mass Index | 3 | 2016 | 866 | 0.080 |
Why?
|
Solvents | 1 | 2008 | 109 | 0.080 |
Why?
|
Myocardial Contraction | 1 | 2009 | 383 | 0.080 |
Why?
|
Kidney | 1 | 2012 | 945 | 0.070 |
Why?
|
Creatinine | 1 | 2008 | 243 | 0.070 |
Why?
|
Equipment Safety | 1 | 2007 | 50 | 0.070 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2007 | 37 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2008 | 174 | 0.070 |
Why?
|
Odds Ratio | 3 | 2016 | 880 | 0.070 |
Why?
|
Radiography, Interventional | 1 | 2007 | 49 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2007 | 82 | 0.070 |
Why?
|
United States | 5 | 2017 | 7338 | 0.070 |
Why?
|
Contraindications | 1 | 2007 | 52 | 0.070 |
Why?
|
Atherectomy, Coronary | 1 | 2006 | 5 | 0.070 |
Why?
|
Congresses as Topic | 1 | 2007 | 85 | 0.070 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 248 | 0.070 |
Why?
|
Comorbidity | 4 | 2013 | 1425 | 0.070 |
Why?
|
Clinical Competence | 1 | 2012 | 657 | 0.070 |
Why?
|
Hospitalization | 2 | 2010 | 977 | 0.070 |
Why?
|
Algorithms | 3 | 2018 | 1195 | 0.070 |
Why?
|
Thrombolytic Therapy | 1 | 2008 | 233 | 0.070 |
Why?
|
Prostheses and Implants | 1 | 2007 | 159 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2010 | 1738 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2009 | 377 | 0.070 |
Why?
|
Patient Compliance | 1 | 2008 | 402 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2008 | 307 | 0.060 |
Why?
|
Kidney Failure, Chronic | 1 | 2008 | 365 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2009 | 378 | 0.060 |
Why?
|
District of Columbia | 3 | 2009 | 23 | 0.060 |
Why?
|
Catheterization | 1 | 2005 | 209 | 0.060 |
Why?
|
Insulin | 1 | 2008 | 617 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 234 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2009 | 738 | 0.060 |
Why?
|
Chronic Disease | 3 | 2019 | 1329 | 0.060 |
Why?
|
Aortic Valve Insufficiency | 2 | 2014 | 47 | 0.050 |
Why?
|
Hypertension | 1 | 2012 | 1533 | 0.050 |
Why?
|
Prevalence | 1 | 2007 | 1609 | 0.050 |
Why?
|
Sternotomy | 1 | 2022 | 18 | 0.050 |
Why?
|
Recovery of Function | 2 | 2018 | 506 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2008 | 694 | 0.050 |
Why?
|
Ultrasonography | 2 | 2015 | 453 | 0.050 |
Why?
|
Young Adult | 3 | 2022 | 5710 | 0.050 |
Why?
|
Ulnar Artery | 1 | 2019 | 2 | 0.040 |
Why?
|
Vasoconstriction | 1 | 2019 | 81 | 0.040 |
Why?
|
Lymphangiogenesis | 1 | 2019 | 10 | 0.040 |
Why?
|
Asia | 1 | 2019 | 59 | 0.040 |
Why?
|
North America | 1 | 2019 | 111 | 0.040 |
Why?
|
Benchmarking | 1 | 2019 | 91 | 0.040 |
Why?
|
Europe | 1 | 2019 | 196 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 648 | 0.040 |
Why?
|
Arterial Occlusive Diseases | 1 | 2019 | 134 | 0.040 |
Why?
|
Adolescent | 3 | 2022 | 8904 | 0.040 |
Why?
|
Hospitals, University | 1 | 2019 | 169 | 0.040 |
Why?
|
Consensus | 1 | 2019 | 211 | 0.040 |
Why?
|
Hydrodynamics | 1 | 2018 | 15 | 0.040 |
Why?
|
Retreatment | 2 | 2007 | 59 | 0.040 |
Why?
|
Partial Thromboplastin Time | 1 | 2017 | 57 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 189 | 0.040 |
Why?
|
Age Factors | 2 | 2013 | 1860 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 334 | 0.030 |
Why?
|
Regression Analysis | 2 | 2008 | 737 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2015 | 5 | 0.030 |
Why?
|
Radiation Exposure | 1 | 2016 | 84 | 0.030 |
Why?
|
Overweight | 1 | 2017 | 186 | 0.030 |
Why?
|
Healthy Volunteers | 1 | 2015 | 78 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2016 | 138 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
Obesity, Morbid | 1 | 2017 | 172 | 0.030 |
Why?
|
Sesquiterpenes | 1 | 2014 | 41 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2015 | 181 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2008 | 1549 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2013 | 57 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 333 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2007 | 929 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
Adenosine | 1 | 2013 | 165 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2013 | 219 | 0.030 |
Why?
|
Radiography | 1 | 2013 | 572 | 0.030 |
Why?
|
Office Visits | 1 | 2012 | 83 | 0.030 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 89 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2011 | 46 | 0.030 |
Why?
|
Drug Resistance | 1 | 2012 | 223 | 0.020 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2012 | 174 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 239 | 0.020 |
Why?
|
Cineangiography | 1 | 2009 | 15 | 0.020 |
Why?
|
Injections, Intra-Arterial | 1 | 2009 | 30 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 100 | 0.020 |
Why?
|
Angiography, Digital Subtraction | 1 | 2009 | 63 | 0.020 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2009 | 20 | 0.020 |
Why?
|
Aorta, Abdominal | 1 | 2009 | 97 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 196 | 0.020 |
Why?
|
Contusions | 1 | 2008 | 11 | 0.020 |
Why?
|
Observation | 1 | 2008 | 30 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2009 | 88 | 0.020 |
Why?
|
Creatine | 1 | 2008 | 30 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2009 | 349 | 0.020 |
Why?
|
Social Class | 1 | 2009 | 127 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 497 | 0.020 |
Why?
|
Pilot Projects | 1 | 2012 | 1341 | 0.020 |
Why?
|
Injections | 1 | 2008 | 119 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2008 | 215 | 0.020 |
Why?
|
Treatment Failure | 1 | 2008 | 216 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2008 | 242 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 567 | 0.020 |
Why?
|
Drug Labeling | 1 | 2007 | 32 | 0.020 |
Why?
|
Cause of Death | 1 | 2008 | 241 | 0.020 |
Why?
|
Aspirin | 1 | 2009 | 295 | 0.020 |
Why?
|
Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 1140 | 0.020 |
Why?
|
Heart Defects, Congenital | 1 | 2009 | 596 | 0.010 |
Why?
|
Brain Ischemia | 1 | 2009 | 665 | 0.010 |
Why?
|
Research Design | 1 | 2007 | 729 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 772 | 0.010 |
Why?
|
Animals | 1 | 2009 | 20880 | 0.010 |
Why?
|